
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which is part of
28 June 2024
("CPH2", the "Company" or the "Group")
Level 1 of Factory Acceptance Test Completed
CPH2, the
The Level 1 FAT signifies a crucial part of the procedure verifying that mechanical and electrical components are checked for completion, confirms that all documentation is in order, and that the MFE's design and build is aligned to the documentation and compliant to relevant safety standards. The successful independent verification was undertaken by
The Company is now proceeding with Level 2 of the FAT protocol, which verifies a broad range of checks and calibrations for the MFE110. Once the functional checks of the MFE110 are completed, CPH2 will begin Level 3 FAT, the final testing procedure once the MFE110 electrolyser has been fully commissioned and is producing hydrogen and oxygen.
The completed FAT of the MFE110 will be the first customer acceptance and validation of CPH2's scaled electrolyser technology marking a significant milestone in the Company's route to market.
"The completion of Level 1 FAT is an important milestone as we continue with the Factory Acceptance Testing of our market-leading technology. Level 1 signifies that we have completed the build of the MFE110 and all necessary checks are complete so we can continue our journey to commercialisation. We will now swiftly move to Level 2 where upon approval of the functional checks, we will commence our final stage, on-site testing of the MFE110."
ENDS
For more information, please contact:
|
via Camarco |
|
|
|
|
Cavendish |
|
|
+44 (0)131 220 9771 |
|
+44 (0)131 220 9772 |
|
+44 (0)131 220 9778 |
|
|
Camarco PR |
+ 44(0) 20 3 757 4980 |
|
|
|
|
Lily Pettifar |
|
To find out more, please visit: https://www.cph2.com
Overview of CPH2
CPH2 is the holding company of
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the